CONMED (NYSE:CNMD) Posts Quarterly Earnings Results, Beats Estimates By $0.14 EPS

CONMED (NYSE:CNMD - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported $1.34 EPS for the quarter, beating analysts' consensus estimates of $1.20 by $0.14, Zacks reports. CONMED had a net margin of 10.13% and a return on equity of 14.60%. CONMED updated its FY 2025 guidance to 4.250-4.400 EPS.

CONMED Trading Down 1.5 %

Shares of CNMD stock traded down $1.04 during mid-day trading on Friday, reaching $66.32. The company's stock had a trading volume of 827,550 shares, compared to its average volume of 463,932. The company's 50 day simple moving average is $70.37 and its 200-day simple moving average is $70.13. The company has a quick ratio of 1.06, a current ratio of 2.27 and a debt-to-equity ratio of 1.01. CONMED has a 12-month low of $61.05 and a 12-month high of $88.60. The firm has a market capitalization of $2.05 billion, a PE ratio of 15.64, a price-to-earnings-growth ratio of 1.05 and a beta of 1.46.

CONMED Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 3rd. Stockholders of record on Friday, December 20th were given a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 1.21%. The ex-dividend date was Friday, December 20th. CONMED's payout ratio is currently 18.87%.

Wall Street Analysts Forecast Growth

Several analysts have commented on CNMD shares. Wells Fargo & Company lowered their target price on shares of CONMED from $74.00 to $70.00 and set an "equal weight" rating for the company in a research note on Thursday. Needham & Company LLC dropped their target price on CONMED from $97.00 to $91.00 and set a "buy" rating for the company in a research note on Thursday. Stifel Nicolaus raised their price target on CONMED from $72.00 to $75.00 and gave the stock a "buy" rating in a research note on Thursday. StockNews.com downgraded shares of CONMED from a "buy" rating to a "hold" rating in a research note on Friday, November 8th. Finally, JPMorgan Chase & Co. cut shares of CONMED from an "overweight" rating to a "neutral" rating and decreased their target price for the stock from $85.00 to $70.00 in a research report on Thursday. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, CONMED has an average rating of "Moderate Buy" and a consensus price target of $77.20.

CONMED Company Profile

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.